StockData
Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc. (ELVN) shareholders

ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$44.89−1.96 (-4.18%)

Close on Nov 18, 2026Market cap $3.29BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
80M of 73M shares
Institutional holders
211
63 new, 18 sold out
Net institutional buying
17M
In Q2 2026
Insider trades, 12 months
0 buys · 73 sales
Net sold $76.47M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Polar Capital Holdings Plc
Joint filing with Polar Capital LLP (8.47%), Polar Capital Funds PLC - Biotechnology Fund (8.47%)
59,800,4068.47%13G (passive) amendmentMar 31, 2026
Abigail P. Johnson
Joint filing with FMR LLC (15.00%)
10,713,54015.00%13G (passive) amendmentJun 30, 2026
Orbimed Advisors LLC
Joint filing with Orbimed Capital Gp Vii LLC (9.20%)
6,774,5079.50%13D (active) amendmentJun 22, 2026
BlackRock, Inc.5,206,5817.10%13G (passive) amendmentSep 30, 2026
Polar Capital LLP
Joint filing with Polar Capital Holdings Plc (8.46%), Polar Capital Funds PLC - Biotechnology Fund (8.46%)
5,056,8078.46%13G (passive) amendmentMar 31, 2026
Michael Kramarz
Joint filing with Commodore Capital LP (7.70%), Commodore Capital Master LP (7.70%) and 1 more
4,800,9407.70%13G (passive) amendmentMar 31, 2026
Vestal Point Capital, LP
Joint filing with Ryan Wilder (6.50%)
3,830,0006.50%13G (passive)Dec 31, 2025
Fairmount Funds Management LLC
Joint filing with Fairmount Healthcare Fund II L.P. (6.30%), Peter Harwin (6.30%) and 1 more
3,711,4446.30%13G (passive) amendmentJun 30, 2025
Ryan Wilder
Joint filing with Vestal Point Capital, LP (5.40%)
3,250,0005.40%13G (passive) amendmentMar 31, 2026
VHCP Management EG, LLC
Joint filing with Venrock Healthcare Capital Partners III, L.P. (5.40%), VHCP Co-Investment Holdings III, LLC (5.40%) and 4 more
3,226,3315.40%13G (passive) amendmentSep 30, 2025
Tomas Kiselak
Joint filing with Fairmount Funds Management LLC (6.60%), Fairmount Healthcare Fund II L.P. (6.60%) and 1 more
3,202,7986.60%13G (passive) amendmentDec 31, 2024
Polar Capital Funds PLC - Biotechnology Fund
Joint filing with Polar Capital Holdings Plc (5.17%), Polar Capital LLP (5.17%)
2,536,8815.17%13G (passive)Jun 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ELVNValueChange% of portfolio
FMR LLC10,025,01713.68%$508.77M+3,195,7710.02%
Orbimed Advisors LLC6,776,6329.25%$343.91M−1,182,9066.37%
Polar Capital Holdings Plc6,430,6368.78%$326.35M+1,364,7030.77%
BlackRock, Inc.4,359,7045.95%$221.25M+674,9970.00%
Vestal Point Capital, LP4,000,0005.46%$203.00M+750,0004.74%
Commodore Capital LP3,275,0004.47%$166.21M–9.90%
Price T Rowe Associates Inc /Md/2,903,9073.96%$147.37M+2,806,1600.01%
Vanguard Capital Management LLC2,569,0023.51%$130.38M+400,8400.00%
Citadel Advisors LLC2,068,9922.82%$105.00M+325,0770.01%
Fairmount Funds Management LLC1,855,6442.53%$94.17M–6.22%
Siren, L.L.C.1,774,4112.42%$90.05M+1,028,1851.82%
Bellevue Group AG1,490,0002.03%$75.62M−830,8671.59%
Geode Capital Management, LLC1,407,2021.92%$71.43M+340,7820.00%
First Light Asset Management, LLC1,360,7501.86%$69.06M+1,158,8834.20%
State Street Corp1,213,6161.66%$61.59M+122,5100.00%
Pictet Asset Management Holding SA1,161,7841.59%$58.96M+232,2400.06%
Adage Capital Partners Gp, L.L.C.1,083,3131.48%$54.98MNew0.08%
Novo Holdings A/S1,000,0001.36%$50.75M−280,0002.95%
First Turn Management, LLC954,3601.30%$48.43M+330,5215.18%
Samlyn Capital, LLC912,6371.25%$46.32MNew0.75%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202621180M100.0%63 / 8748 / 1825M7M
Q1 202617063M86.2%64 / 6332 / 1918M14M
Q4 202512662M85.2%20 / 4645 / 268M5M
Q3 202513459M81.1%20 / 5932 / 105M5M
Q2 202512460M81.2%24 / 5723 / 2013M3M
Q1 202512150M68.1%22 / 4235 / 132M2M
Q4 202411350M67.7%22 / 4525 / 114M3M
Q3 202410248M65.1%20 / 4123 / 106M4M
Q2 20249349M66.8%32 / 3615 / 128M4M
Q1 20247445M60.9%16 / 2621 / 37M2M
Q4 20236239M53.4%8 / 2412 / 72M2M
Q3 20236139M53.3%6 / 2222 / 82M2M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

207 funds held ELVN in Q2 2026, 34% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ELVNValue% of fundAs of
Vanguard Total Stock Market Index Fund1,883,3722.57%$95.58M0.00%Jun 30, 2026
Fidelity Small Cap Growth Fund1,250,7541.71%$68.55M0.78%Jul 31, 2026
Select Health Care Portfolio1,120,0001.53%$44.32M0.77%May 31, 2026
iShares Russell 2000 ETF1,117,2411.52%$56.70M0.07%Jun 30, 2026
T. Rowe Price New Horizons Fund, Inc.807,3291.10%$40.97M0.28%Jun 30, 2026
Fidelity Advisor Health Care Fund670,0000.91%$36.72M1.18%Jul 31, 2026
Fidelity Small Cap Growth K6 Fund648,1140.88%$35.52M0.77%Jul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.647,4540.88%$32.86M0.28%Jun 30, 2026
Vanguard Extended Market Index Fund624,6750.85%$31.70M0.03%Jun 30, 2026
Fidelity Stock Selector Small Cap Fund579,6910.79%$31.77M0.43%Jul 31, 2026
Fidelity Advisor Biotechnology Fund501,3680.68%$27.48M1.25%Jul 31, 2026
Fidelity Small Cap Index Fund468,4940.64%$25.68M0.08%Jul 31, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund468,2480.64%$23.76M0.24%Jun 30, 2026
Small Cap Growth Fund427,9010.58%$23.45M0.42%Jul 31, 2026
Fidelity U.S. Equity Central Fund400,0000.55%$20.30M0.09%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Richard A. FairPRESIDENT AND CEO, Director––Dec 12, 2025
Samuel KintzPRESIDENT AND CEO, Director890,3921.22%Nov 19, 2025
Benjamin HohlCHIEF FINANCIAL OFFICER38,0000.05%Oct 21, 2026
Helen Louise CollinsCHIEF MEDICAL OFFICER25,0000.03%Oct 21, 2026
Joseph P. LyssikatosCHIEF SCIENTIFIC OFFICER758,9381.04%Feb 17, 2026
Anish PatelCHIEF OPERATING OFFICER235,0110.32%Feb 17, 2026
Lori Anne KunkelDirector52,9250.07%Nov 3, 2026
Kristine M. BallDirector––Oct 16, 2026
J. Scott GarlandDirector0–Oct 5, 2026
Mika K. DerynckDirector87,3730.12%Aug 6, 2026
Richard A. HeymanDirector146,3200.20%Feb 19, 2026
Jake BauerDirector87,3720.12%Feb 17, 2026
Rahul D. BallalDirector22,3410.03%Feb 17, 2026
Rishi GuptaDirector7,663,34910.46%Feb 17, 2026
Andrew John PhillipsDirector––Feb 10, 2025
Capital GP VII LLC OrbiMed10% owner7,663,34910.46%Jun 24, 2026
Advisors Llc Orbimed10% owner219,4050.30%Jun 24, 2026
Genesis GP LLC OrbiMed10% owner8,661,22511.82%Jun 24, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Lori Anne Kunkel
Director
Oct 30, 2026Option exercise+7,300$18.30$133.59K52,925
Lori Anne Kunkel
Director
Oct 30, 2026Option exercise+3,741$1.12$4.19K45,625
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Oct 19, 2026Sale(10b5-1 plan)−6,018$38.48$231.55K38,000
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Oct 19, 2026Option exercise+6,018$14.85$89.37K44,018
Helen Louise Collins
CHIEF MEDICAL OFFICER
Oct 19, 2026Sale(10b5-1 plan)−5,000$38.47$192.34K25,000
Helen Louise Collins
CHIEF MEDICAL OFFICER
Oct 19, 2026Option exercise+5,000$2.48$12.40K30,000
J. Scott Garland
Director
Oct 1, 2026Sale−13,000$46.67$606.72K0
J. Scott Garland
Director
Oct 1, 2026Option exercise+13,000$15.47$201.11K13,000
Helen Louise Collins
CHIEF MEDICAL OFFICER
Sep 17, 2026Sale(10b5-1 plan)−240$51.48$12.36K25,000
Helen Louise Collins
CHIEF MEDICAL OFFICER
Sep 17, 2026Option exercise+5,000$2.48$12.40K30,000
Helen Louise Collins
CHIEF MEDICAL OFFICER
Sep 17, 2026Sale(10b5-1 plan)−2,916$50.03$145.89K27,084
Helen Louise Collins
CHIEF MEDICAL OFFICER
Sep 17, 2026Sale(10b5-1 plan)−1,844$50.71$93.51K25,240
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Sep 17, 2026Sale(10b5-1 plan)−289$51.49$14.88K38,000
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Sep 17, 2026Sale(10b5-1 plan)−2,194$50.72$111.28K38,289
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Sep 17, 2026Sale(10b5-1 plan)−3,535$50.03$176.86K40,483
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Sep 17, 2026Option exercise+3,982$14.85$59.13K44,018
Helen Louise Collins
CHIEF MEDICAL OFFICER
Aug 17, 2026Sale(10b5-1 plan)−1,100$59.35$65.29K25,000
Helen Louise Collins
CHIEF MEDICAL OFFICER
Aug 17, 2026Option exercise+5,000$2.48$12.40K30,000
Helen Louise Collins
CHIEF MEDICAL OFFICER
Aug 17, 2026Sale(10b5-1 plan)−3,900$58.37$227.64K26,100
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Aug 17, 2026Sale(10b5-1 plan)−1,388$59.35$82.38K40,036
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Aug 17, 2026Sale(10b5-1 plan)−4,630$58.35$270.16K41,424
Mika K. Derynck
Director
Aug 4, 2026Option exercise+87,373$2.48$216.69K87,373
Mika K. Derynck
Director
Aug 4, 2026Option exercise+27,567$25.28$696.89K114,940
Mika K. Derynck
Director
Aug 4, 2026Option exercise+23,364$14.85$346.96K138,304
Mika K. Derynck
Director
Aug 4, 2026Option exercise+20,491$22.47$460.43K158,795
Mika K. Derynck
Director
Aug 4, 2026Sale(10b5-1 plan)−158,795$60.21$9.56M0
Helen Louise Collins
CHIEF MEDICAL OFFICER
Jul 17, 2026Sale(10b5-1 plan)−459$51.55$23.66K29,310
Helen Louise Collins
CHIEF MEDICAL OFFICER
Jul 17, 2026Sale(10b5-1 plan)−231$50.05$11.56K29,769
Helen Louise Collins
CHIEF MEDICAL OFFICER
Jul 17, 2026Option exercise+5,000$2.48$12.40K30,000
Helen Louise Collins
CHIEF MEDICAL OFFICER
Jul 17, 2026Sale(10b5-1 plan)−63$53.92$3.40K25,000
Helen Louise Collins
CHIEF MEDICAL OFFICER
Jul 17, 2026Sale(10b5-1 plan)−2,184$53.42$116.67K25,063
Helen Louise Collins
CHIEF MEDICAL OFFICER
Jul 17, 2026Sale(10b5-1 plan)−2,063$52.39$108.08K27,247
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Jul 17, 2026Sale(10b5-1 plan)−2,564$52.32$134.15K48,815
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Jul 17, 2026Sale(10b5-1 plan)−369$51.48$19.00K51,379
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Jul 17, 2026Sale(10b5-1 plan)−324$49.97$16.19K51,748
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Jul 17, 2026Option exercise+1,072$2.48$2.66K52,072
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Jul 17, 2026Sale(10b5-1 plan)−2,638$53.38$140.82K46,177
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Jul 17, 2026Sale(10b5-1 plan)−123$53.87$6.63K46,054
Lori Anne Kunkel
Director
Jul 6, 2026Sale(10b5-1 plan)−4,111$49.98$205.47K47,773
Lori Anne Kunkel
Director
Jul 6, 2026Sale(10b5-1 plan)−5,889$50.84$299.40K41,884
Advisors Llc Orbimed
10% owner
Jun 22, 2026Sale−1,477$45.00$66.47K219,405
Advisors Llc Orbimed
10% owner
Jun 22, 2026Sale−787,024$45.38$35.72M6,601,878
Advisors Llc Orbimed
10% owner
Jun 22, 2026Sale−46,776$45.00$2.10M6,555,102
Advisors Llc Orbimed
10% owner
Jun 22, 2026Sale−24,846$45.38$1.13M220,882
Helen Louise Collins
CHIEF MEDICAL OFFICER
Jun 17, 2026Sale(10b5-1 plan)−1,133$44.74$50.69K25,000
Helen Louise Collins
CHIEF MEDICAL OFFICER
Jun 17, 2026Sale(10b5-1 plan)−2,599$43.87$114.02K26,133
Helen Louise Collins
CHIEF MEDICAL OFFICER
Jun 17, 2026Sale(10b5-1 plan)−1,268$42.83$54.31K28,732
Helen Louise Collins
CHIEF MEDICAL OFFICER
Jun 17, 2026Option exercise+5,000$2.48$12.40K30,000
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Jun 17, 2026Sale(10b5-1 plan)−1,379$42.79$59.01K55,639
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Jun 17, 2026Sale(10b5-1 plan)−3,401$43.86$149.17K52,238
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Jun 17, 2026Sale(10b5-1 plan)−1,238$44.75$55.40K51,000
Benjamin Hohl
CHIEF FINANCIAL OFFICER
Jun 17, 2026Option exercise+6,018$2.48$14.92K57,018
Advisors Llc Orbimed
10% owner
Jun 15, 2026Sale−272,322$45.02$12.26M7,388,902
Advisors Llc Orbimed
10% owner
Jun 15, 2026Sale−9,086$45.02$409.05K245,728
Lori Anne Kunkel
Director
Jun 5, 2026Sale(10b5-1 plan)−1,867$35.36$66.02K52,238
Lori Anne Kunkel
Director
Jun 5, 2026Sale(10b5-1 plan)−7,779$34.28$266.66K54,105
Lori Anne Kunkel
Director
Jun 5, 2026Sale(10b5-1 plan)−354$35.82$12.68K51,884
Helen Louise Collins
CHIEF MEDICAL OFFICER
May 18, 2026Sale(10b5-1 plan)−223$41.21$9.19K25,000
Helen Louise Collins
CHIEF MEDICAL OFFICER
May 18, 2026Option exercise+5,000$2.48$12.40K30,000
Helen Louise Collins
CHIEF MEDICAL OFFICER
May 18, 2026Sale(10b5-1 plan)−3,475$39.53$137.37K26,525

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
18.22%
10M shares short
Days to cover
5.7
At 2M shares a day
Change since last report
+10.3%
From 9M shares
Short volume, 20 days
63.6%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Enliven Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 28,913 shares on Sep 10, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Helen Louise Collins
Director
Oct 19, 202615,000$559.80KOct 19, 2026Stock Options
Jeffrey Garland
Director
Oct 1, 202613,000$606.72KOct 1, 2026Stock Option Exercise
Benjamin Hohl
Officer
Sep 17, 202612,036$591.21KSep 17, 2026Long shares from previous exercised options
Richard A. Heyman
resigned from BOD
Sep 4, 202638,000$2.25MSep 4, 2026Stock Options Exercise
Mika K. Derynck
Director
Aug 4, 2026158,795$9.22MAug 4, 2026Stock Options
Helen Louise Collins
Officer
Jul 17, 202615,000$762.90KJul 17, 2026Stock Options
OrbiMed Genesis Master Fund, L.P.
Shareholder
Jun 22, 202626,323$1.21MJun 22, 2026Merger
OrbiMed Private Investments VII, LP
Shareholder
Jun 22, 2026833,800$38.32MJun 22, 2026Merger
The Biotech Growth Trust PLC
Shareholder
Jun 22, 202631,132$1.43MJun 22, 2026Merger
Benjamin Hohl
Officer
Jun 17, 202618,054$768.20KJun 17, 2026Stock Option Exercise
OrbiMed Genesis Master Fund, L.P.
Shareholder
Jun 15, 20269,086$384.88KJun 15, 2026Merger
OrbiMed Private Investments VII, LP
Shareholder
Jun 15, 2026272,322$11.54MJun 15, 2026Merger
The Biotech Growth Trust PLC
Shareholder
Jun 15, 202610,243$433.89KJun 15, 2026Merger
Lori Anne Kunkel
Board Member
Jun 5, 202620,000$709.80KJun 5, 2026Pre-IPO Shares
Helen Louise Collins
Officer
May 18, 202615,000$620.10KMay 18, 2026Stock Options

See a number that looks wrong?